Two randomised phase II trials of intermittent intravenous versus subcutaneous alpha-2 interferon alone (Trial 1) and in combination with 5-fluorouracil (Trial 2) in advanced colorectal cancer


Sixty-five patients with advanced colorectal cancer were randomised to one of two schedules of recombinant alpha-2 interferon (IFN). In the first study, 36 patients received single-agent IFN, either 50×106 U/m2 intravenously on 5 consecutive days every 4 weeks, or 20×106 U/m2 subcutaneously three times per week. No tumour responses were seen and toxicity… (More)
DOI: 10.1007/BF01648994


1 Figure or Table